A2780

A2780 is a human ovarian endometrioid adenocarcinoma cell line, originally established in 1972 from an untreated patient with advanced-stage disease. Its singular scientific advantage resides in its status as the chemotherapy-sensitive parental archetype for isogenic drug resistance research. Unlike heterogeneous patient samples, A2780 provides a pure, syngeneic background against which resistance mechanisms can be experimentally isolated.

The line's power lies in its derivative platform. Chronic exposure of A2780 to cisplatin and adriamycin has generated the widely adopted resistant sublines A2780cis and A2780ADR, which exhibit cross-resistance to melphalan, vinblastine, and irradiation. This matched pair enables precise dissection of ATP-binding cassette (ABC) transporter efflux (MDR1/BCRP), EMT programming (VIM, SNAIL1/2), and ECM-mediated chemoprotection-mechanisms often confounded in non-isogenic comparisons.

Genomically, A2780 harbors clinically relevant driver mutations in TP53, BRCA1, PTEN (homozygous deletion), PIK3CA, and ATM. It retains stable, authenticated STR profiles and forms tumors in nude mice, bridging monolayer screening and in vivo efficacy. Critically, A2780 is exquisitely amenable to 3D multicellular spheroid culture, a configuration that recapitulates solid tumor hypoxia, G0-G1 cell cycle arrest, and p27-mediated chemoresistance-features lost in 2D.